Rapport Therapeutics Inc. (RAPP)
RAPP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$28.99
-3.85% on the day
Market cap
$1.4B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | RAPP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0002012593 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-10 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 231 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.4% |
| 1 month | -33.7% |
| 3 months | -29.5% |
| Year to date | -6.8% |
| 1 year | +8.0% |
| From 52-week high | -46.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KLRA | Kailera Therapeutics Inc. | $10.77 | -4.94% | $1.4B |
| AAPG | Ascentage Pharma Group International American Depository Shares | $15.06 | -1.63% | $1.4B |
| OMER | Omeros Corporation | $18.88 | -3.82% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.59 | -0.98% | $1.3B |
| KRSA | Korsana Biosciences Inc. | $31.66 | -6.99% | $1.4B |
| PCRX | Pacira BioSciences Inc. | $36.31 | -0.11% | $1.4B |
| STOK | Stoke Therapeutics Inc. | $22.50 | -6.83% | $1.5B |
| RARE | Ultragenyx Pharmaceutical Inc. | $14.92 | -2.48% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier